Quick Answer
BriaCell Therapeutics Corp. reported Shares Outstanding of 1.88 million shares for fiscal year 2025.
BriaCell Therapeutics Corp. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 1.88M | +539.3% |
| 2025 | 294,694 | +141.7% |
| 2024 | 121,907 | -99.2% |
| 2023 | 15.98M | +3.0% |
| 2022 | 15.52M | +1.6% |
| 2021 | 15.27M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| August 31, 2025 | 1.88M | — | +0.0% |
| July 31, 2025 | 1.88M | +54.5% | -71.3% |
| April 30, 2025 | 6.56M | -59.0% | +2125.4% |
| January 31, 2025 | 294,694 | -98.2% | -99.2% |
| October 31, 2024 | 36.18M | +126.4% | +2868.3% |
| July 31, 2024 | 1.22M | -92.4% | -92.4% |
| April 30, 2024 | 15.98M | +3.0% | +0.0% |
| January 31, 2024 | 15.98M | +3.0% | +0.0% |
- BriaCell Therapeutics Corp. showed an increase of +539.3% in Shares Outstanding compared to the prior fiscal year.
- Over the 2021–2025 period, BriaCell Therapeutics Corp.’s shares outstanding has declined by 87.7% (from 15.27 million shares to 1.88 million shares).
- The most recent figure is from BriaCell Therapeutics Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on October 16, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: